ARTICLE | Product Development
AACR data suggest Agenus’ next-generation CTLA-4 blocker may expand responding patient group
April 12, 2021 10:21 PM UTC
BCIQ Company Profiles
BCIQ Target Profiles
Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) (CTLA4) (CD152)